Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Brain & Development|March 1, 2017
Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndromeReem Rafik AlOlaby, Stefan R Sweha, Marisol Silva, et al.Proceedings of the National Academy of Sciences of the United States of America|April 24, 2023
Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomasMateus Mota, Stefan R Sweha, Matt Pun, et al.Eneurologicalsci|October 4, 2017
Clinical and molecular correlates in fragile X premutation femalesPoonnada Jiraanont, Stefan R Sweha, Reem R AlOlaby, et al.Cancer Cell|August 16, 2020
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine GliomasChan Chung, Stefan R Sweha, Drew Pratt, et al.Nature Communications|October 17, 2024
Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline gliomaNneka E Mbah, Amy L Myers, Peter Sajjakulnukit, et al.Science Translational Medicine|October 13, 2021
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomasStefan R Sweha, Chan Chung, Siva Kumar Natarajan, et al.Neuro-Oncology|May 23, 2022
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline gliomaDana Messinger, Micah K Harris, Jessica R Cummings, et al.Nature|February 4, 2026
ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expressionSiva Kumar Natarajan, Joanna Lum, James Haggerty Skeans, et al.Cancer Cell|May 16, 2025
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosisDerek Dang, Akash Deogharkar, John McKolay, et al.Cancer Discovery|August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.Pageof 1